Search

everythinglearnresearchcommunity

for

Search:↓

Some newly made compounds can block an enzyme linked to hair loss and prostate growth, with one in particular being very selective.

Loss of the p53 gene alone causes tumors, and losing both p53 and Rb genes speeds up aggressive skin cancer.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Tofacitinib is a promising treatment for children with rheumatic diseases.

The compound (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile can stimulate hair growth and reduce oil production when applied topically.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Cepharanthine helps reduce cell aging caused by the cancer drug Doxorubicin by boosting cell cleanup processes.

Short-term treatment with ROCKi increases skin cell growth without changing stem cell features.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

TS-13 speeds up hair regrowth after chemotherapy without affecting treatment effectiveness.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

TSC2-/meth cells can cause skin lesions, hair growth, and lung issues, and may be treated with chromatin remodeling agents.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

Tofacitinib treatment for hair loss may worsen acne.

Tofacitinib, a hair regrowth treatment, may worsen acne.

TAK-279 effectively reduces psoriasis symptoms and is safe.

miR-325-3p can slow down brain tumor growth by targeting FOXM1.

A new engineered treatment shows promise in curing heart fibrosis.

Topical tacrolimus reduces certain growth factors in hair follicles.

The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.

Topical calcitriol-analogs can reduce hair loss caused by chemotherapy.

The folate-cyclodextrin conjugate targets cancer cells more precisely, potentially reducing chemotherapy side effects.

Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.

A new triple drug system using nanoparticles effectively targets breast tumors in 3D models.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.